ABSTRACT
INTRODUCTION
Recently, oligonucleotides have been discovered as reagents that can bind to specific nucleotide sequences of cellular genes or RNAs and thereby arrest gene expression (1) . Two strategies for oligonucleotide reagents have been used. The best known involves antisense oligonucleotides, which bind mRNA to inhibit its processing or translation. The second is the triplex strategy which employs single-stranded DNA oligonucleotides that bind to the major groove of a double-stranded target DNA to form a triplehelix or 'triplex' in a sequence-specific manner (2) (3) (4) . The triplex strategy has certain advantages over the antisense RNA strategy, which include fewer and less regenerative targets (single copy genes vs. multiple copy mRNAs). When triplex-forming oligonucleotides (TFOs) are targeted to a vital promoter region of a test gene, they have been shown to selectively repress transcription in a dose-dependent manner and to interfere with the function of sequence-specific DNA binding proteins such as restriction enzymes and transcription factors, both in vitro and in cultured cells (2, (4) (5) (6) (7) (8) . We have chosen to use TFOs containing natural deoxyguanosine and deoxythymidine residues, with selective and high affinity DNA binding at physiological pH (9, 10) , in attempting to block progesterone-dependent gene transcription.
The influence of progesterone on the physiology of female mammals and birds is profound (11) . Along with estrogen, these steroid hormones control the growth, differentiation, and function of reproductive tissues and others by affecting gene expression. Progesterone and estrogen also influence the growth of many tumors, including those of breast and uterine origin. Therefore, control of steroid hormone action is of major importance, as witnessed by increasing use of antihormones in reproductive control and cancer treatment (12, 13) . The molecular mechanism of progesterone action involves binding and activation of a nuclear receptor, which binds a specific DNA sequence present in the promoters of progesterone-responsive genes to activate their transcription (14) . The most common therapeutic agents aimed at disrupting progesterone action are progesterone analogs that bind, but do not activate, the receptor. When given systematically, these agents affect all progesterone-regulated body processes and may cause certain unwanted side effects.
Here, we report both in vitro and in vivo inhibition of progesterone-induced gene expression by a potent, sequencespecific TFO which binds to a target containing progesterone response elements (PREs). The mechanism of transcriptional inhibition is shown to be direct competition between the TFO and the progesterone receptor for binding to the PRE-containing DNA target.
MATERIALS AND METHODS Oligonucleotide synthesis and target construction
Oligonucleotides were synthesized with standard DNA bases (9) . The target site ( Figure 1 ) was synthesized as two oligonucleotides with Bgl II and BamH I sites on their 5' ends. After annealing, these were cloned into the Bgl II site of pLovTATA (15) in front of a 400 bp G-free cassette to construct the pPREPLov template. The G-free cassette was used in in vitro transcription to yield G-less transcripts of a discrete length (400bp) in the presence of no GTP, a chain-terminating analog (3'-0-methyl-GTP) and Tl RNase, which cleaves at G's. The target site was also inserted in the BamH I site of pBLCAT2 (16) just upstream of the thymidine kinase promoter. This PREPtkCAT plasmid showed progesterone-dependent expression of the chloramphenicol acetyltransferase (CAT) reporter gene. All TFOs and controls were modified to contain a 3' propylamine group (9) . Cholesterylmodified oligonucleotides were synthesized with a cholesterol phosphoramidite reagent on a Milligen 8700 oligonucleotide synthesizer (ref. 17 with modifications; K. Jayaraman, manuscript in preparation). Oligonucleotides with cholesterol moieties on their 3 ends were purified on a Mono Q FPLC (Pharmacia) column in 10 mM NaOH at the 1.0 M point of a NaCl gradient.
TFO binding to the target site
The target was radiolabelled to high specific activity on the purine-rich strand by EcoRI cleavage of the pPREPLov plasmid and filling in with Klenow and 32 P-dATP and dTTP. After Sac I digestion, the 89 bp fragment was gel purified and used in both band shift and footprint analyses. Band shift assays were conducted as described in ref. 9 in 20 mM Mg ++ at 37°C. DNase I footprinting was done exactly as described in ref. 9 . The migration of radiolabeled molecular weight markers was used to identify the target site.
TFO inhibition of progesterone receptor binding
The target oligonucleotides were annealed and labeled with Klenow and ^P-dGTP and -dATP. After gel purification, the target was incubated with TFOs at four times higher than final concentration in 20 mM HEPES, pH 7.9, 24 mM MgCl 2 and 4 mM spermidine. After incubation for 30 min. at 20°C, components were added to the following final concentrations: sheared 50 /tg/ml herring sperm DNA, 45 mM KC1 + NaCl, 20 mM HEPES, pH 7.9, 2mM dithiothreitol, 6 mM MgCl 2 , 1 mM spermidine, and 50 nM chicken progesterone receptor. The latter was purified as described in ref. 16 . Final reaction volumes were 20 /tl. After 10 min. at 20°C, 10 /tl aliquots were loaded on a 4% (29:1) Tris/borate gel and a 5% (19:1) Tris/borate/Mg ++ (5mM) gel. Gels were dried and exposed to Kodak XAR film for five days. Control reactions lacking progesterone receptor (not shown) showed no difference in triplex formation compared to those with receptor ( Figure 4 ).
TFO inhibition of progesterone receptor-dependent transcription in vitro
The pPREPLov construct was used as a test template in a cellfree transcription assay modified from that described in ref. 15 . To construct the control template PREPLovEGFR, we cloned a synthetic fragment harbouring a promoter fragment of the epidermal growth factor receptor gene in the HindHI site of pPREPLov (9) . The pPREPLov (100 ng) and AdML200 (25 ng) templates were preincubated in 4 /tl with TFOs at concentrations five times higher than final in 12.5mM HEPES, pH 7.9, 12.5mM MgCl 2 , and 6.25 mM spermidine at 20°C for 30 min. Next, a reaction mix containing buffers, nucleotides (including 32 P-UTP and 3' O-methyl GTP), Tl RNase, and herring sperm DNA (750 ng/reaction) was added so that final concentrations described in ref. 15 , except that MgCl 2 was 6 mM and spermidine was 1 mM. Either progesterone receptor (one pmole) or BSA was also added at that time. After incubation at 20°C for 10 min, fractions of HeLa nuclear extract (DE175, DE500, and S300-II, ref. 18 ) were added to start transcription. Reactions were stopped after 45 min and processed for loading on sequencing gels, which were dried and exposed to Kodak XAR film (15) . Bands from low exposure auto radiograms of two identical experiments were quantitated with an LKB Ultroscan XL laser densitometer. Specific transcripts from pPREPLov were normalized to internal control AdML signals and basal transcription (without progesterone receptor) was subtracted.
Measurement of cellular uptake of oligonucleotides
For cell uptake experiments, TFOs were 5' end-labeled usinĝ S-ATP and polynucleotide kinase as described elsewhere (19) except that unincorporated counts were removed by gel filtration on a 1X20 cm Sephadex G-100 column. CV-1 cells were grown to near confluence, trypsinized and transferred to 24 well dishes at a density of 100,000 cells per well. After incubation for 24 hours at 37°C, labeled oligonucleotide was added so that each well contained 2X10 6 cpm at a concentration of 1/tM. Cells were harvested at 1, 3, 6, and 12 hours and fractionated essentially as described by Orson et al. (6) . All samples were then analyzed by liquid scintillation counting. Cell counts and volumes were determined with a hemocytometer and a Coulter Channelizer, respectively.
TFO inhibition of transcription In transiently transfected cells
Monkey kidney-derived CV-1 cells were grown in Dulbecco's minimal essential medium with 5% (v/v) charcoal-stripped serum. Transient transfections of 3.6 X10 5 cells on 60 mm plates were done with polybrene (20) . Plasmid DNA containing pSV2CAT (ref. 21, 1.25 /tg) or pPREPtkCAT (0.3 /tg) and the chicken progesterone receptor expression vector p79K (ref. 22 , 0.25 /tg) was adjusted to a total of 5 /tg per plate with pUC19. After transfection, cells were allowed to recover before incubation with one ml of medium containing TFOs. After 6 h, progesterone was added to 10~7 M. Another 6 h later, cells were harvested, lysed, and extracted protein was assayed by die Bradford mediod (BioRad). Ten /tg of cell extract protein was assayed for CAT activity with 25 /tg butyryl CoA and 0.2 /tCi of [ 3 H] -chloramphenicol (New England Nuclear) in a 100 /tl volume (23) . After 37°C incubation overnight, the assays were extracted with tetramethylpentadecane:xylene (2:1, v/v) and the organic phase was counted. Oligonucleotide treatment and progesterone-free control transfections were done in triplicate, while fully active pSV2CAT (untreated) and pPREPtkCAT (progesterone-induced) transfections were done in replicates of six. Full CAT activity for pSV2CAT was determined by subtracting background counts of the extraction assay from untreated experimental counts. For progesterone-induced CAT activities, the average CAT activity from control plates widiout progesterone was subtracted. After background subtraction, counts for CAT assays of oligonucleotide-treated plates were compared to the fully active values to generate % activities. The% activities of four separate experiments were averaged to produce the data shown in Fig. 7 . Standard errors were calculated from the variance determined by the Lotus 1-2-3 spreadsheet program.
RESULTS

Design of TFOs and the PRE-containing target
Double-stranded DNA target sites for triple-helix formation are presently limited to sequences with segregation of purine and pyrimidine residues to opposite strands. We engineered such a high affinity TFO target site based on a well characterized sequence containing tandemly repeated PRE elements of the tyrosine aminotransferase gene (Figure 1 ). Only the sequence between the PREs was altered to create a purine-rich linker. When the new sequence was cloned into the pLov G-free reporter construct, 20 bp upstream of a TATA box, in vitro transcription of the pPREPLov G-free reporter responded to progesterone receptor just as did the original PRE-containing construct (15) .
The 'PRE2ap' TFO was designed according to rules previously established (9) : for every A:T pair, it contains a T' and for each G:C pair, a 'G' (Figure 1 ). Its polarity is antiparallel to the purine-rich strand of the target sequence, as previously determined for TFOs of this base composition (9) . The 38 bp length confers good binding strength and specificity. When bound, TFOs of this kind occupy the major groove of the target double-stranded DNA helix. The region of the target protected from DNase I digestion by the PRE2ap TFO (indicated by the overlined sequence in Figure 1 ) overlaps more than one halfsite of each PRE (arrows). Since progesterone receptor has been shown to bind as dimers to each PRE (24) , alteration of one halfsite should interfere with binding to the entire PRE. In addition, binding of progesterone receptor dimers to neighboring PREs is cooperative, so inhibition of binding at one site will also reduce binding at the other (25) .
Other oligonucleotides, chosen as controls, are also shown in Fig. 1 . 'PRE2p' has the PRE2ap sequence inverted in a strand of opposite polarity. Due to the near dyad symmetry of the target, the PRE2p TFO could bind the target as it is drawn in Figure 1 , antiparallel to the purine-rich strand but the binding would be unstable due to mismatches in the target center (underlined). The 'CTR1' and 'CTR2' controls contain sequences of G and T residues that are similar to PRE2ap in length and G/T ratio.
Only the PREjap TFO forms a triplex on the target PREs
Initial testing of TFOs was done on the target sequence in bandshift assays. The radiolabelled double-stranded DNA target was incubated with increasing amounts of specific and control TFOs. The PRE2ap TFO formed a triplex with the target (see Figure 2 ). The observed Kj of 100 nM showed that the PRE2ap had a high affinity for the target site. No triplexes were formed with either CTR1 (Figure 2) , PRE2p, or CTR2 (data not shown) control oligonucleotides, even at concentrations ten-fold higher than the Kj of the specific PRE2ap TFO.
To map the contact of the TFO, DNase I footprinting was performed. The specific PRE2ap TFO bound to the target sequence, which was radio-labeled on the 3' end of the purinerich strand. Limited DNase I digestion yielded a series of fragments arising from cleavage sites present all along the target except at those regions protected by the bound TFO (Figure 3) . The extent of the footprint is shown as an overlined sequence in Figure 1 . The strongest protection was seen over a 27 base pair region, including the purine-rich sequence between the two PREs. Adjacent PRE halfsites were protected, including the G residues which are known to be important for contacting progesterone receptors (25) . Identical reactions utilizing identical concentrations of the closely related PRE2p control TFO showed no significant DNase I protection ( Figure 3) ; similarly, no protection was observed with the CTR1 control (data not shown). We conclude that PRE2ap is a sequence-specific TFO that binds the PRE target sequence with high affinity.
The PRE2ap TFO prevents progesterone receptor binding to the target PREs
Progesterone receptors are known to bind the major groove of the double-stranded PRE site (26) . Since the specific TFO bound half of each PRE, we predicted that PRE2ap binding would totally eliminate the binding of progesterone receptors. To test this, we altered the band shift assay conditions to optimize both TFO and progesterone receptor binding. TFO and progesterone receptor band shifts could not be assayed on one gel: without Mg ++ in the gel, DNA triplexes dissociated during electrophoresis, and with Mg ++ in the gel, progesterone receptor: DNA complexes aggregated and did not enter the gel. Therefore, we performed double-size reactions and ran one half of each on Tris/borate and
TFO: PRE2ap
y\r> *-* Figure 1 . The progesterone-responsive target sequence and triplex-forming oiigonucleotides. The double-stranded DNA sequence targeted for triplex formation is shown at the top. It contains two well-characterized progesterone response elements from the tyrosine aminotransferase gene (PREs, half-sites indicated by arrows) separated by a linker with high purine/pyrimidine asymmetry. The PRE2ap triplex-forming oligonucleotide (TFO) was designed to bind to the duplex target by Hoogsteen or reverse Hoogsteen base-triplets to form an amiparallel DNA triplex as shown. Orientations of DNA strands are indicated at their ends. Three control oligonucleotides are shown: PRE2p, CTR1, and CTR2. The first could bind the target in the antiparallel orientation as drawn, but contains two destabilizing mismatches in that orientation (underlined). The extent of DNase I protection by the PRE2ap TFO (Figure 3) is overlined on the target sequence.
CTR1 <3Duple x Figure 2 . The PRE2ap TFO forms triplexes with high affinity on PRE-coffiaining targets. Band shift analyses were performed with the radiolabelled double-stranded target sequence described in Figure 1 . Increasing concentration of the PRE2ap TFO resulted in triplex formation, as observed by the appearance of a triple helix with reduced electrophoredc mobility. The CTR1 control oligonucleotide showed no triplex formation, as did PRE2p and CTR2 controls (not shown). Tris/borate/MgCl 2 gels (Figure 4) . On the Mg ++ containing gel, dose-dependent formation of triplexes on the target was seen with the addition of PRE2ap, but not the control TFO. Triplex formation was slightly less stable in this gel assay system (5 mM Mg ++ ) compared to the previous band shift system (20 mM Mg ++ ), as seen by the apparently incomplete formation of triplexes and the higher concentration of TFO required. The Tris/borate gel allowed the receptor: DNA complexes to enter and showed progesterone receptor-dependent shifts of the radiolabelled target DNA to positions consistent with the binding of one or two progesterone receptor dimers, the functional PREbinding moieties (25) . In the presence of the specific PRE2ap TFO, however, progesterone receptor binding was severely reduced. The control oligonucleotide did not appear to affect binding of the receptor. Because progesterone receptor binding was almost completely blocked, triplex formation was most likely complete on the target during the binding incubation. These experiments suggest that the PRE2ap TFO competes with progesterone receptors for binding to the PREs since triplex formation directly correlated to inhibition of progesterone receptor binding.
The PRE2ap TFO inhibits progesterone receptor dependent transcription in vitro
To test whether PRE2ap could inhibit progesterone receptor function in an in vitro transcription assay developed in our laboratory, the original template (15) was minimally altered to contain a purine-rich sequence in the linker region between the two PREs ( Figure 1) in front of the G-free cassette. Transcription of this new pPREPLov template was strongly induced by added progesterone receptor in the presence of HeLa cell extract ( Figure 5A ). The adenovirus major late promoter linked to a shorter G-free cassette was used as an internal control in all assays.
To see if the PRE2ap TFO could interrupt in vitro transcription, the TFO was allowed to bind to the template to form a triplex. Even at a final concentration of 25 nM, PRE2ap significantly reduced progesterone receptor-dependent transcription while adenovirus control transcription was unaffected ( Figure 5A ). At 100 nM, progesterone receptor-dependent transcription was inhibited to below basal levels while the adenoviral promoter was only minimally affected. Control TFO CTRl, shown here at the highest level tested (200 nM), showed minimal inhibition of test template transcription. The two other control oligonucleotides also did not specifically inhibit progesterone-dependent transcription in vitro. Two identical assays were quantitated on a densitometer from films exposed in their gray (linear) range ( Figure 5B ). Levels of progesterone receptor-dependent transcription of the target template decreased proportionally with increasing concentrations of TFO. The range in relative activities at 50, 100, and 200 nM TFO were 19 to 8%, 1 to -3% and -2 to -6%, respectively. Maximal transcriptional repression was achieved at 100 and 200 nM PRE2ap, while adenovinis major late controls and controls with the CTRl oligonucleotide showed little reduction in transcription. At the highest TFO concentration tested, eight-fold higher than that of the midpoint of PRE2ap inhibition, the control oligonucleotide reduced test template transcription by less than 40%. To exclude the possibility that triplex formation on the testtemplate distorts the structure of the DNA in such a way that it decreases the rate of transcription, we constructed the PREPLovEGFR template. A fragment from the promoter of the human epidermal growth factor receptor (EGFR) gene was cloned downstream of the G-free cassette of PREPLov. In vitro transcription analysis was performed using this template and the TFO EG36ap, which was shown before to form a stable triplex on the EGFR target site (9) . In contrast to the PRE2ap TFO the EG36ap TFO had no effect on transcription directed by the progesterone receptor ( Figure 5C ). Therefore, we conclude that PRE2ap inhibits progesterone receptor-dependent transcription by displacing receptor binding to PREs with potency and specificity. 
Cholesterol-modification of oligonucleotides enhances their cellular uptake
To progress toward in vivo studies, we began tests with oligonucleotides added to the medium of cultured cells. Earlier work (6) (7) (8) had shown that oligonucleotides associate readily with cells so that intracellular and extracellular concentrations equilibrate. Other groups have shown that cholesterolderivatization of oligonucleotides results in their preferential association with cells, driving their uptake to 10-to 100-fold higher levels than those for underivatized oligonucleotides (27) . In order to determine the effect of cholesterol addition to the 3' end of PRE2ap and CTR2 oligonucleotides on cellular and nuclear uptake, CV-1 cells were incubated with 35 S-labeled oligonucleotides and then fractionated into nuclear and 'cytosolic' fractions. Figure 6 shows the results of experiments in which the uptake of PRE2ap, cholesterol-modified PRE2ap, CTR2 and cholesterol-modified CTR2 was measured in CV-1 cells. These results demonstrate that 3'amine oligonucleotides equilibrate in CV-1 cells so that the intranuclear concentration approaches that in the external medium (1/tM see Fig. 6 , panels A and C). At the same treatment levels, however, both PRE2ap and CTR2 cholesterol-modified oligonucleotides preferentially accumulate in nuclei to reach approximately four-fold higher concentrations (4 nM, see Fig. 6 , panels B and D). These results are unlikely to be related to differential degradation, since all 3'-modified oligonucleotides tested have very slow degradation when compared to that for unmodified molecules (6, and references therein). The success of the cholesterol-derivatization in enhancing the nuclear concentration of oligonucleotides led us to test the modified PRE2ap TFO in transiently transfected cells.
Cholesterol-PRE2ap inhibits progesterone-dependent transcription in vivo
We tested the PRE2ap TFO with and without cholesterolderivatization for inhibition of progesterone-dependent transcription in cultured cells. The PRE2ap target sequence in Fig. 1 was cloned upstream of the thymidine kinase promoter and the CAT reporter gene in PREPtkCAT. CAT activity in transiently transfected CV-1 monkey kidney cells was dependent on cotransfection with a progesterone receptor expression vector and treatment with progesterone. After recovery from the transfection procedure, cells were treated with oligonucleotides in their medium and, later, progesterone. The 3'-amine PRE2ap oligonucleotide at 60 /tM medium concentration showed a marginal inhibition (about 20%) of progesterone-dependent CAT activity but control pSV2CAT activity was also affected (data not shown). The CTR1 control at 20/tM did not significantly repress CAT activity. Cholesterol-PRE2ap, however, specifically inhibited progesterone action even at 10 /tM (Fig. 7) . Four sequential transfection studies done in triplicate were averaged to produce the data shown in Fig. 7 . The pPREPtkCAT reporter showed about 30% inhibition with treatment of 10 /tM cholesterol-PRE2ap, while at 20 /tM, inhibition was almost 50%. Higher concentrations of cholesterol-oligonucleotide (30 and 40 /tM) appeared to significantly reduce the amount of protein extracted and were not included in the study. The control cholesterol-CTR2 oligonucleotide showed moderate inhibition (less than 15%) of the reporter gene at the highest concentration tested (20 /tM). Transcription from the pSV2CAT reporter was totally unaffected by the presence of 20 /tM cholesterol-PRE2ap. Thus, the cholesterol-derivative of the PRE2ap TFO acts in living cells to significantly suppress gene activation by the progesterone receptor.
DISCUSSION
The purpose of this study was to selectively inhibit the activity of a steroid-regulatable mammalian transcription factor which shows high affinity and specificity for its cis-element. This was accomplished at the gene level with a novel class of inhibitory agents, single-stranded DNA TFOs. Although triplexes were recognized decades ago in studies of homopolymer strands, only recently have they been investigated on complex sequences. The current limitation of this technology is that TFO target sequences must contain a purine-rich strand of DNA. The residues of the third strand from Hoogsteen or reverse Hoogsteen base triplets so that G or protonated C (pKj=4.5) residues bind G:C Watson-Crick pairs while T residues bind A:T Watson-Crick pairs. Although most studies have employed pyrimidine-rich TFOs, we chose to use G-rich TFOs due to their binding stability at physiological pH. The G-T class of TFOs has been shown to bind antiparallel to the purine-rich strand of the target with high sequence specificity and affinity (9, 10) . This was demonstrated for our PRE2ap TFO using band shift and DNase I footprint assays. Demonstration of TFO inhibition of progesterone receptor binding to DNA directly correlated to triplex formation in a modified band shift assay. By inhibiting the progesterone receptor binding, the PRE2ap TFO was able to completely repress progesterone receptor-dependent transcription in vitro.
The repression of progesterone receptor-directed in vitro transcription by the PRE2ap TFO was dramatic. In the complex transcription assay conditions, specific inhibition of transcription by PRE2ap occurred with a Kj of 25 nM, slightly less than the 100 nM value observed in band shift assays. This difference could be a result of supercoiling of the plasmid template or stabilization by components of nuclear extract (proteins, polyamines) that favor TFO binding. In addition, TFO binding may disrupt DNA structure at the transcription start site so that even basal transcription levels are inhibited. The Kj for triplex formation by PRE2ap compared favorably with those described in other studies (6) (7) (8) . The triplex was stable at 37°C during the extended incubation periods used in the transcription assay. Previously, other methods of inhibiting progesterone receptor-driven transcription have been tested in this assay system (15, 28, 29) . If double-stranded PRE oligonucleotide sites are used to prevent progesterone receptor binding to the transcription template, the effective molar ratios required for repression (25 to 50-fold double-stranded PRE oligonucleotide to template ratio) are similar to those for the TFO (our 25 nM midpoint of repression translates to only a 15-fold molar excess of TFO to target gene PRE element). This is probably due to the similar affinities of the receptor and the TFO for the PRE target, as seen in the dual band shift assay. However, even at a 100-fold molar excess of double-stranded competitor PREs in the transcription assay, total repression is unattainable (15, 28) . Incomplete inhibition is also seen if the progesterone receptor antagonist RU486 is used (29) . Thus, it appears that the TFO mechanism of interrupting transcription of genes may account for higher potency of these reagents than those which attempt to inhibit all of a much larger population of targets, such as nuclear receptors. Since in vitro transcription conditions mimic those of the cell nucleus, these data encouraged us to test the PRE2ap TFO was as a potential PRE-binding agent and inhibitor of progesterone receptor action in vivo.
As the first test of TFO inhibition of progesterone receptordependent transcription in vivo, transient transfectiori assays were performed. Although similar studies with c-myc, HTV, and the interleukin-2 receptor-a genes demonstrated specific inhibition, the initial results with the PRE2ap oligonucleotide were poor. Therefore, the PRE2ap TFO was derivatized with cholesterol in an attempt to enhance its intracellular concentration. Cellular uptake experiments indicated that cholesterol-modified molecules were preferentially concentrated in cell nuclei to four-fold higher levels than those in the medium. These results indicated that the cholesterol-oligonucleotides should be more effective than 3'-amine-derivatized oligonucleotides that equilibrate across the cell membrane. The results in transfected cells were remarkable, with inhibition seen at 10 /tM cholesterol-PRE2ap, progressing to almost 50% inhibition at 20 jiM. The increased inhibitory action of the cholesterol-modified PRE2ap is most likely due to its enhanced concentration at the site of TFO action: the nucleus. The specificity of the intracellular inhibition was shown by the absence of TFO mediated inhibition on reporter gene activity driven by SV40 promoter, as well as by the lack of inhibition of a control cholesterol-oligonucleotide on the target gene. Since cholesterol-derivatized PRE2ap and CTR2 oligonucleotides both accumulated equally in cell nuclei, the in vivo potency of the PRE2ap TFO in the inhibition of transcription must be due to its sequence-specific properties. Although the medium concentrations required for inhibition were higher than those used in vitro, they were similar to those used in other studies (6, 8) . This is the first demonstration of enhanced effectiveness of a triple helix forming oligonucleotide drug by cholesterol-modification. Such advances in drug delivery hold promises of low doses of oligonucleotides effectively controlling steroid hormone receptor action in the future.
Potential applications of triplex technology exist in many areas of science and medicine. Triplexes are thought to occur naturally during recombination and transcriptional control events. These sequence-specific triplex reagents are proving their value in diverse areas, from selecting a single site in a human chromosome for enzymatic manipulation (30) to inhibiting viral replication (31) . Chemical modifications of TFOs are being studied to improve their affinity for DNA and to relieve the requirement for a homopurine target strand. This should provide more DNA sequences available to bind TFOs, including those of cis-elements other than the PREs described here (32) , transcription start sites (33) , and elongation regions (34) . There is also the potential for direction of reagents capable of permanent DNA damage by such TFOs, thereby increasing potency and decreasing effective doses in triplex inhibition of transcription (35) . Oligonucleotide uptake by cells is surprisingly good, and is also being enhanced by recent advances in chemically-modified oligonucleotides, such as addition of cholesterol (27) . The long term goal of oligonucleotide therapy in animals already has been realized with the antisense class of reagents (36) . Since the antisense reagents have similar structures and binding affinities to TFOs, their success in in vivo is encouraging for triplex therapeutics. With the affinity and specificity of TFOs, such as the one described here, TFOs may develop into effective alternatives to antihormones and other reagents that will be useful in research and medicine.
